Alignment Healthcare (ALHC) Q4 2025 earnings review
A Breakout Year: Exceptional Growth Meets Real Profitability
Alignment Healthcare capped off a milestone 2025 with a massive Q4 beat across all key metrics. Driven by 25% membership growth, the company surged to $3.95B in annual revenue (+46% YoY) while turning a corner on profitability. Management’s proprietary care model successfully navigated industry headwinds, generating a record $110M in Adjusted EBITDA and positive Free Cash Flow for the year. Looking ahead, 2026 guidance projects further revenue acceleration past the $5B mark. While competitors retreat due to regulatory pressures, Alignment is heavily capturing market share without sacrificing margins.
🐂 Bull Case
Membership grew 25% in Q4 to 236,300, and 2026 guidance implies another massive ~25% leap to nearly 300,000 members. Alignment is successfully taking advantage of industry dislocation as legacy incumbents exit markets or cut benefits.
The company dramatically reversed its cash flow profile, printing over $113M in Free Cash Flow in 2025 after burning cash in previous years. Their scalable, capital-light model is finally achieving true operating leverage.
🐻 Bear Case
With hyper-growth, a massive chunk of Alignment's membership sits in Year-1 or Year-2 cohorts. These newly acquired members inherently carry higher Medical Benefit Ratios (MBR). If the company fails to engage them clinically, margins could slip.
The final phase-in of the V28 risk model and ongoing Part D changes related to the Inflation Reduction Act (IRA) present a continuous, unpredictable operating environment for Medicare Advantage plans.
⚖️ Verdict: 🟢🟢
Highly Bullish. The company is delivering top-tier 40%+ revenue growth while simultaneously expanding margins and generating strong free cash flow. In an incredibly difficult Medicare Advantage environment where giants are stumbling, Alignment is proving its tech-driven care model is a durable competitive moat.
Key Themes
Stars Ratings Driving a Widening Competitive Moat
A stable, crucial driver for Alignment is its CMS Star Ratings. With 100% of members in 4-star or higher plans for the upcoming payment year (including two 5-star contracts in NV and NC), Alignment possesses a massive funding advantage. This allows them to offer richer benefits than competitors, creating a virtuous cycle of membership growth.
AVA Platform Keeping Medical Costs in Check
The core engine behind the company's margin expansion is its AVA AI clinical platform. By directly managing risk and maintaining low inpatient admission rates (historically in the low 140s per 1,000), Alignment improved its full-year Medical Benefits Ratio (MBR) from 88.8% in 2024 to an impressive 87.5% in 2025.
Capitalizing on Industry Disruption (Macro)
The Medicare Advantage macro environment is highly turbulent. Tightening V28 risk adjustment and IRA Part D impacts are forcing larger incumbents to aggressively cut benefits or exit certain counties. Alignment is leveraging its structural cost and Stars advantages to confidently play offense, accelerating market share grabs.
Expected Q4 Margin Seasonality Executed
Adjusted EBITDA decelerated sequentially from $32.4M in Q3 to $11.4M in Q4. While expected due to the flu season and Part D utilization timing, the higher MBR (87.7% in Q4 vs 86.7% in Q2) requires monitoring to ensure respiratory season severity doesn't structurally damage the 2026 baseline.
Managing the Maturation Curve of Surging Growth
With 2026 guided to add another ~60,000 net new members, Alignment’s clinical teams face the operational burden of onboarding and assessing these lives. Management noted in prior quarters that new members typically start with an ~89% MBR before maturing to higher profitability over 3-5 years. Any friction in deploying the AVA platform to these new cohorts poses an earnings risk.
Other KPIs
Reversing heavily from a negative $(6.6) million FCF in FY24. This validates management's prior claim that they would achieve company-wide free cash flow positivity in 2025. This self-funding capability removes dilution risk as they fuel geographic expansion.
Accelerating 42% YoY compared to $87.9 million in 24Q4. The gross profit expansion cleanly translates to the bottom line, proving that their SG&A infrastructure is scaling efficiently against the booming top line.
Guidance
Decelerating slightly in percentage terms (+30.7% YoY implied at the midpoint vs +46.1% in FY25), but represents massive absolute dollar growth. Breaking the $5 billion barrier demonstrates robust market acceptance of their product structure.
Accelerating profitability. The midpoint of $148 million implies a 34.6% YoY growth. This shows that despite aggressive expansion, Alignment is maintaining strong pricing discipline and expects to continuously leverage its G&A base.
Accelerating heavily from the Q4 base of 236,300. Capturing almost 50,000 net new lives in the Q1 open enrollment window validates the "market share grab" thesis management set out earlier in the year.
Key Questions
V28 Impact and Bidding
With the final phase-in of the V28 risk model approaching, how did this specific headwind factor into your 2026 benefit design and membership growth guidance?
M&A for Supplemental Benefits
In prior quarters, you discussed tuck-in M&A for 'ancillary captives' (like dental or behavioral) to capture more premium spend. Given your strong $113M free cash flow generation, is this M&A strategy actively being deployed for 2026?
Onboarding the Massive 2026 Cohort
You are guiding to nearly 50,000 new lives arriving in Q1 alone. What early indications are you seeing from the AVA platform regarding initial clinical stratification and engagement rates for this immense new cohort?